Notwithstanding promising clinical results, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant difficulty from PBMs. The insurers are often creating limitations to access, such as high cost restrictions and approval processes that hinder consumer access. Market suggest that these a